Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Alternative Checkpoints As Targets For Immunotherapy

Ayush Pant, Ravi Medikonda, M. Lim
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Immunotherapy has shown an unprecedented response in treatment of tumors. However, challenges such as lack of cytotoxic lymphocytes to mount an immune response or development of resistance to therapy can limit efficacy. Here, we discuss alternative checkpoints that can be targeted to improve cytotoxic lymphocyte function while harnessing other components of the immune system. Blockade of alternative checkpoints has improved anti-tumor immunity in mouse models and is being tested clinically with encouraging findings. In addition to modulating T cell function directly, alternative checkpoints can also regulate activity of myeloid cells and regulatory T cells to affect anti-tumor response. Combination of immune checkpoint inhibitors can improve treatment of tumors by activating multiple arms of the immune system.
This paper references
10.1038/ncomms8657
Corrigendum: An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction.
C. Zhu (2015)
10.4049/jimmunol.173.4.2500
Murine B7-H3 Is a Negative Regulator of T Cells1
D. V. Prasad (2004)
10.1172/jci.insight.121157
CD226 opposes TIGIT to disrupt Tregs in melanoma.
J. Fourcade (2018)
10.4049/jimmunol.173.9.5445
B7-H3 Enhances Tumor Immunity In Vivo by Costimulating Rapid Clonal Expansion of Antigen-Specific CD8+ Cytolytic T Cells1
Liqun Luo (2004)
B 7-H 3 is a potent inhibitor of human T cell activation : No evidence for B 7-H 3 and TREML 2 interaction
J. Leitner (2012)
10.1038/nature13848
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Yu-Hwa Huang (2015)
10.1038/ni967
The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses
Woong-Kyung Suh (2003)
10.1002/eji.200839028
B7‐H3 is a potent inhibitor of human T‐cell activation: No evidence for B7‐H3 and TREML2 interaction
J. Leitner (2009)
10.1016/S0022-5347(08)60301-8
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome.
X. Zang (2007)
10.1002/hep.25777
Tim‐3/galectin‐9 signaling pathway mediates T‐cell dysfunction and predicts poor prognosis in patients with hepatitis B virus‐associated hepatocellular carcinoma
H. Li (2012)
10.4049/jimmunol.0800185
LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis1
C. Workman (2009)
10.1038/85339
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
A. Chapoval (2001)
B 7 - H 3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen - specific CD 8 + Cytolytic T cells
L Luo (2004)
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
10.1002/hep.26938
Liver-primed CD8+ T cells suppress antiviral adaptive immunity through galectin-9-independent T-Cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice
Joseph S. Dolina (2014)
10.1186/1479-5876-12-97
MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial
E. Romano (2013)
10.1089/mab.2013.0052
Murine b7-h3 is a co-stimulatory molecule for T cell activation.
R. Yan (2013)
10.1038/ni1271
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C. Zhu (2005)
Clinical significance and regulation of the costimulatory molecule B 7 - H 3 in human colorectal carcinoma
J Sun (2010)
22:126 cells
(2017)
10.1007/BF03239969
An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo
C. Lupu (2012)
10.1158/0008-5472.CAN-13-1506
VISTA Regulates the Development of Protective Antitumor Immunity.
I. Le Mercier (2014)
10.1200/JCO.2017.35.15_SUPPL.9520
Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.
P. Ascierto (2017)
PD - 1 H ( VISTA ) – mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus
X Han (2019)
CD 155 T / TIGIT signaling regulates CD 8 + T - cell metabolism and promotes tumor progression in human gastric cancer
W He
10.1073/pnas.0903474106
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
N. Stanietsky (2009)
10.1016/j.cell.2018.11.010
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
J. Wang (2019)
10.1084/jem.20100619
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
L. Wang (2011)
10.1084/jem.20081752
DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors
S. Gilfillan (2008)
10.1172/JCI80445
TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Joe-Marc Chauvin (2015)
A phase i study of IMP 321 and gemcitabine as the front - line therapy in patients with advanced pancreatic adenocarcinoma
A Wang-Gillam (2013)
Expression of Tim-3 in gastric cancer tissue and its relationship with prognosis.
G. Cheng (2015)
10.1084/jem.20100643
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi (2010)
10.1007/s00262-015-1752-y
Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression
Alberto Sada Japp (2015)
10.1038/nm.4308
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Jianjun Gao (2017)
10.4049/jimmunol.173.11.6806
Biochemical Analysis of the Regulatory T Cell Protein Lymphocyte Activation Gene-3 (LAG-3; CD223)1
N. Li (2004)
10.4049/jimmunol.164.11.5583
A Soluble Lymphocyte Activation Gene-3 Molecule Used as a Vaccine Adjuvant Elicits Greater Humoral and Cellular Immune Responses to Both Particulate and Soluble Antigens1
S. El mir (2000)
10.1101/648899
Clonal replacement of tumor-specific T cells following PD-1 blockade
K. E. Yost (2019)
10.1007/s10637-012-9866-y
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
A. Wang-Gillam (2012)
10.1073/pnas.1811067116
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
J. Blando (2019)
10.1016/J.IMMUNI.2004.08.010
Role of LAG-3 in regulatory T cells.
C. Huang (2004)
10.18632/oncotarget.9035
The co-stimulatory molecule B7-H3 promotes the epithelial-mesenchymal transition in colorectal cancer
B. Jiang (2016)
10.1038/sj.bjc.6605375
Clinical importance of B7-H3 expression in human pancreatic cancer
I. Yamato (2009)
10.1158/1078-0432.CCR-09-0068
A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
C. Brignone (2009)
Clinical importance of B 7 - H 3 expression in human pancreatic can
I Yamato (2009)
10.1158/0008-5472.CAN-11-1620
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Seng-Ryong Woo (2012)
10.1111/pcmr.12599
Immunoregulatory protein B7‐H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells
K. Flem-Karlsen (2017)
Dual PD 1 / LAG 3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia
M Wierz (2018)
10.1038/srep18266
A Dual Role of Graphene Oxide Sheet Deposition on Titanate Nanowire Scaffolds for Osteo-implantation: Mechanical Hardener and Surface Activity Regulator
W. Dong (2015)
10.1182/blood-2017-06-792267
Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.
Marina Wierz (2018)
10.1126/science.1148536
Promotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune Cells
A. Anderson (2007)
10.18632/oncotarget.18251
Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma.
Zhi-Zhang Yang (2017)
10.1182/blood-2018-01-825265
TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma.
Camille Guillerey (2018)
Galectin-9 increases Tim-3[+] dendritic cells and CD8[+] T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions
永原 慶子 (2009)
10.1038/modpathol.2017.89
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
H. Kakavand (2017)
10.1073/pnas.1003345107
Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
J. Matsuzaki (2010)
10.4049/jimmunol.1100660
Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models
D. Flies (2011)
10.1038/nrclinonc.2017.44
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Tsukasa Shibue (2017)
10.1158/1078-0432.CCR-17-2852
B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
K. Yonesaka (2018)
10.1016/j.cellimm.2008.01.006
The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft.
F. Wang (2007)
10.1158/0008-5472.CAN-17-0381
CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer.
W. He (2017)
10.1111/j.1365-2567.2004.02087.x
LAG‐3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors
S. Buisson (2005)
10.1186/1479-5876-8-71
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
C. Brignone (2010)
This study analyzed tumor microenvironment of checkpoint blockade sensitive and resistant tumors (melanoma and pancreatic ductal adenocarcinomas respectively) and identified VISTA as a potent
J Blando (2019)
10.1126/science.1261669
Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53
K. W. Yoon (2015)
10.1182/blood-2008-10-185884
Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation.
M. Nakayama (2009)
10.1016/J.CCR.2007.04.017
Genes that distinguish physiological and pathological angiogenesis.
S. Seaman (2007)
10.1158/2326-6066.CIR-14-0072
VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy
J. L. Lines (2014)
10.1093/neuonc/noz185
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.
J. D. de Groot (2019)
10.1158/1078-0432.CCR-15-2626
T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
Y. Kong (2016)
10.1038/s41423-019-0305-2
Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy
D. Cai (2019)
10.1080/2162402X.2018.1466769
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
A. Hung (2018)
10.1038/s41590-018-0217-9
LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
Takumi Maruhashi (2018)
10.1016/j.ygyno.2013.10.038
Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96.
J. Fauci (2014)
10.1038/nature08512
HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses
H. Yanai (2009)
10.4049/jimmunol.1003081
Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
Nicole Joller (2011)
10.1038/cr.2017.90
Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function
Young-hee Lee (2017)
10.1038/ni.2376
Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
S. Chiba (2012)
10.1111/imm.13001
VSIG‐3 as a ligand of VISTA inhibits human T‐cell function
J. Wang (2019)
10.1172/JCI81187
TIGIT predominantly regulates the immune response via regulatory T cells.
S. Kurtuluş (2015)
This study discovered a major ligand for LAG-3 and showed that the ligand FGL1 is upregulated in some human cancers and associates with poot outcomes in anti-PD-1 treated patients
•• Wang (2018)
10.1038/srep15659
Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer
Chiao-Wen Kang (2015)
10.1126/sciimmunol.aay1863
Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
Laura Strauss (2020)
10.1126/scitranslmed.aax1159
PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus
Xue Han (2019)
This study showed the expansion of T cells following anti-PD-1 therapy for basal and squamous cell carcinoma were of clones that were not in the tumor prior to treatment
•• Yost (2019)
Murine B 7 - H 3 is a negative regulator of T cells
Prasad DVR (2004)
10.1002/ijc.31661
Expression of LAG‐3 and efficacy of combination treatment with anti‐LAG‐3 and anti‐PD‐1 monoclonal antibodies in glioblastoma
Sarah Harris-Bookman (2018)
10.1016/j.jaad.2019.03.012
Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes.
W. Lee (2019)
10.1007/s00262-010-0841-1
Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma
J. Sun (2010)
Promotion of tissue inflammation by on innate immune cells
AC Anderson (2007)
10.1038/s41577-019-0221-9
Defining ‘T cell exhaustion’
C. Blank (2019)
10.4049/jimmunol.168.8.3874
Maturation and Activation of Dendritic Cells Induced by Lymphocyte Activation Gene-3 (CD223)1
S. Andreae (2002)
10.1038/sj.emboj.7601520
Metalloproteases regulate T‐cell proliferation and effector function via LAG‐3
N. Li (2007)
10.1126/science.aaa8172
The future of immune checkpoint therapy
P. Sharma (2015)
The B 7 family member B 7 - H 3 preferentially down - regulates T helper type 1 - mediated immune responses
WK Suh (2003)
10.1016/j.cell.2017.06.007
De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation
Hazem E. Ghoneim (2017)
10.1007/s00262-017-1968-0
Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma
L. Wu (2017)
10.4049/jimmunol.181.11.7660
Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions1
Keiko Nagahara (2008)
10.1158/2326-6066.CIR-14-0150
Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
Theodore Kouo (2015)
10.1038/s41416-018-0313-5
VISTA expressed in tumour cells regulates T cell function
Kumuluzi Mulati (2018)
10.1038/nrc3239
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
10.1158/1078-0432.CCR-15-1535
Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Jennifer E. Kim (2016)
10.1084/JEM.176.2.327
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens
E. Baixeras (1992)
10.1158/0008-5472.CAN-13-2690
LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses.
F. Xu (2014)
10.1016/j.jtho.2017.01.019
LAG‐3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD‐1/PD‐L1 and Tumor‐Infiltrating Lymphocytes
Y. He (2017)
10.1038/ni.1674
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
X. Yu (2009)
10.1016/j.lungcan.2009.01.017
Diagnosis value of serum B7-H3 expression in non-small cell lung cancer.
G. Zhang (2009)
10.1038/s41586-019-1674-5
VISTA is an acidic pH-selective ligand for PSGL-1
Robert J. Johnston (2019)
10.1186/s12943-019-1091-2
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Shuang Qin (2019)
10.3892/ol.2018.9059
Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer
H. Liao (2018)
10.1073/pnas.0709802104
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
X. Zang (2007)
Murine B 7 - H 3 is a co - stimulatory molecule for T cell activation
R Yan (2013)
10.1002/eji.201344392
Enhanced suppressor function of TIM‐3+FoxP3+ regulatory T cells
A. Gautron (2014)



Semantic Scholar Logo Some data provided by SemanticScholar